These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30808293)

  • 21. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin.
    Zasowski E; Butterfield JM; McNutt LA; Cohen J; Cosler L; Pai MP; Gottwald J; Chen WZ; Lodise TP
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3804-13. PubMed ID: 24752270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
    Eljaaly K; Wali H; Basilim A; Alharbi A; Asfour HZ
    Int J Antimicrob Agents; 2019 Aug; 54(2):149-153. PubMed ID: 31173864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System.
    Hsu JL; Siroka AM; Smith MW; Holodniy M; Meduri GU
    Int J Infect Dis; 2011 Jun; 15(6):e382-7. PubMed ID: 21393043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial Resistance and Clinical Outcomes in Nursing Home-Acquired Pneumonia, Compared to Community-Acquired Pneumonia.
    Kang YS; Ryoo SR; Byun SJ; Jeong YJ; Oh JY; Yoon YS
    Yonsei Med J; 2017 Jan; 58(1):180-186. PubMed ID: 27873512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
    Gentile I; Buonomo AR; Corcione S; Paradiso L; Giacobbe DR; Bavaro DF; Tiseo G; Sordella F; Bartoletti M; Palmiero G; Vozza A; Vena A; Canta F; Moriello NS; Congera P; Karruli A; Tascini C; Viale P; Bono VD; Falcone M; Carbonara S; Mikulska MK; Bassetti M; Durante-Mangoni E; De Rosa FG; Maraolo AE
    Int J Antimicrob Agents; 2023 Jul; 62(1):106817. PubMed ID: 37061102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
    Lodise TP; Anzueto AR; Weber DJ; Shorr AF; Yang M; Smith A; Zhao Q; Huang X; File TM
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1119-26. PubMed ID: 25487791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and prognostic risk factors of healthcare-associated pneumonia in a Korean tertiary teaching hospital.
    Ahn JH; Lee KH; Chung JH; Shin KC; Lee CK; Kim HJ; Choi EY
    Medicine (Baltimore); 2017 Oct; 96(42):e8243. PubMed ID: 29049213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of microbiological samples in the hospital management of community-acquired, nursing home-acquired and hospital-acquired pneumonia in older patients.
    Putot A; Tetu J; Perrin S; Bailly H; Piroth L; Besancenot JF; Bonnotte B; Chavanet P; d'Athis P; Charles PE; Sordet-Guépet H; Manckoundia P
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):489-95. PubMed ID: 26753994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia.
    Lee H; Park JY; Lee T; Lee YJ; Lim HJ; Park JS; Yoon HI; Lee JH; Lee CT; Cho YJ
    Korean J Intern Med; 2016 May; 31(3):525-34. PubMed ID: 26968189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Experience of Ceftobiprole for Community- and Hospital-Acquired Pneumonia from a Stewardship Perspective.
    Corcione S; De Benedetto I; Carlin M; Pivetta EE; Scabini S; Grosso C; Shbaklo N; Porta M; Lupia E; De Rosa FG
    Microorganisms; 2024 Apr; 12(4):. PubMed ID: 38674669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
    Brown RB; Iannini P; Gross P; Kunkel M
    Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
    Kaye KS; Udeani G; Cole P; Friedland HD
    Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy.
    Maruyama T; Fujisawa T; Ishida T; Ito A; Oyamada Y; Fujimoto K; Yoshida M; Maeda H; Miyashita N; Nagai H; Imamura Y; Shime N; Suzuki S; Amishima M; Higa F; Kobayashi H; Suga S; Tsutsui K; Kohno S; Brito V; Niederman MS
    Clin Infect Dis; 2019 Mar; 68(7):1080-1088. PubMed ID: 30084884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.